SCHEMBL7429031

SCHEMBL7429031

CN(CCc1ccc(Cl)c(Cl)c1)CCC1CCCN1C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 20/20 0.74
CYP1A2 P05177 4/20 0.62
TP53 P04637 3/20 0.62
CYP2D6 P10635 3/20 0.62
TSHR P16473 3/20 0.62
CYP3A4 P08684 2/20 0.60
GRIN2D O15399 1/20 0.60
GRIN3B O60391 1/20 0.60
GRIN1 Q05586 1/20 0.60
GRIN2A Q12879 1/20 0.60
GRIN2B Q13224 1/20 0.60
GRIN2C Q14957 1/20 0.60
GRIN3A Q8TCU5 1/20 0.60
ALDH1A1 P00352 3/20 0.53
MAPT P10636 2/20 0.53
CYP2C19 P33261 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.50
OPRK1 P41145 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5935280 0.96 SIGMAR1 (0.80) SIGMAR1CYP1A2TP53CYP2D6TSHR
SCHEMBL5935249 0.95 SIGMAR1 (0.79) SIGMAR1CYP1A2TP53CYP2D6TSHR
SCHEMBL7442708 0.85 SIGMAR1 (1.00) SIGMAR1CYP1A2TP53CYP2D6TSHR
SCHEMBL466865 0.77 SIGMAR1 (1.00) SIGMAR1CYP1A2TP53CYP2D6TSHR
SCHEMBL678162 0.77 SIGMAR1 (1.00) SIGMAR1CYP1A2TP53CYP2D6TSHR
Bromide SCHEMBL467371 0.76 SIGMAR1 (0.97) SIGMAR1CYP1A2TP53CYP2D6TSHR
SCHEMBL12648455 0.76 SIGMAR1 (1.00) SIGMAR1CYP1A2TP53CYP2D6TSHR
SCHEMBL8334387 0.74 SIGMAR1 (0.56) SIGMAR1CYP1A2TP53CYP2D6TSHR
SCHEMBL7429044 0.73 SIGMAR1 (0.58) SIGMAR1
SCHEMBL14376817 0.72 SIGMAR1 (0.44) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5571832-A Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS disorders THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-11-05 US disclosed